IP Library Granted Patent US 11,077,054
Granted Patent B2
US 11,077,054 · App. 17/073,312 · Granted Aug 3, 2021

Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia

Inventor: Praful Doshi (San Diego, CA)
A61K9/0051A61K31/5377A61L27/54A61L31/06A61L31/10A61L31/145A61L31/16B33Y80/00C08F2/20C08F2/48C08F220/28C08L33/08C08L33/10G02B1/043A61L12/00A61L12/084A61L12/143A61L2300/00A61L2300/436A61L2420/08C08L33/066C08L39/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,054
App. No.
17/073,312
Granted
Aug 3, 2021
Kind
B2
Abstract

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.

Claims (55)

1. A contact lens; comprising:

a) a first surface and a second surface; and

b) said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens;

1) said at least one coating comprising at least one three dimensional structure; and

2) said at least one three dimensional structure comprising:

a. one or more drug reservoir layers:

wherein said one or more drug reservoir layers comprise one or more drugs; and

b. one or more barrier layers:

wherein said one or more barrier layers modulate the release of said one or more drugs from said contact lens; and

c. at least one Penetration Enhancer (PE).

2. The contact lens of claim 1 ,

wherein said PE can be released from said contact lens when operably engaged with the surface of the eye of a subject.

3. The contact lens of claim 1 ,

wherein said PE can act to enhance the penetration of at least one of said one or more drugs through ocular tissues.

4. The contact lens of claim 1 ,

wherein said at least one coating comprising one or more drugs and comprising PE is provided at least in part by inkjet printing.

5. The contact lens of claim 1 ,

wherein said contact lens is steam sterilized.

6. The contact lens of claim 1 , further wherein said contact lens is provided in a packaging solution.

7. The contact leans of claim 1 ,

further wherein said contact lens is in a packaging solution having a pH between about 6.5 and about 7.8.

8. The contact lens of claim 1 ,

wherein said PE is released from said contact lens, as compared to said one or more drugs, simultaneously, separately, one after other or a combination thereof.

9. The contact lens of claim 1 ,

wherein said PE is provided in liposomes, dendrimers, polymeric nanoparticles, cell penetrating peptides, or a combination thereof.

10. The contact lens of claim 9 ,

wherein said cell penetrating peptide is TAT (derived from transactivator of transcription of human immunodeficiency virus), CC12, PNT (Penetratin), RGD (arginine-glycine-aspartic acid), or a combination thereof.

11. The contact lens of claim 1 ,

wherein said one or more drugs, said PE, or a combination thereof, is provided in microemulsion, micelles, encapsulation, nanoparticle, microspheres, liposomes, ethosomes, niosomes, biodegradable nanoparticles, temperature sensitive smart particles, or combination thereof.

12. The contact lens of claim 1 ,

wherein said one or more drugs are released from said contact lens in an effective amount to treat or prevent a disease, disorder, or condition of a subject.

13. The contact lens of claim 12 ,

wherein said one or more drugs can treat, control, reduce the severity, or reduce the progression of a disease, disorder, or condition in a subject.

14. The contact lens of claim 13 ,

wherein said one or more drugs is Flurbiprofen, Acetazolamide, ethylenediaminetetraacetic acid, palmitoyl carnitine, sodium caprate, sodium dodecylsulphate, sodium deoxycholate, poly oxyethylene-g-lauryl ether, 1-α-lysophosphatidylocholine, deoxycholate, taurodeoxycholate, glycocholate, benzalkonium chloride, or a combination thereof.

15. The contact lens of claim 12 ,

wherein said subject is a human subject.

16. The contact lens of claim 12 ,

wherein said disease, disorder, or condition that is treated is an inflammation, an allergy, an infection, glaucoma, macular degeneration, a parasite, dry eye, eye discomfort, neovascular Age-Related Macular Degeneration (wet AMD), dry Age-Related Macular Degeneration (dry AMD), diabetic retinopathy, or a combination thereof.

17. The contact lens of claim 1 ,

wherein said one or more drugs comprises at least one small molecule drug, at least one biological drug, at least one encapsulated drug, at least one nanoparticle, at least one dispersed drug, or a combination thereof.

18. The contact lens of claim 17 ,

wherein said at least one biological drug comprises at least one protein comprising at least one enzyme, at least one transport protein, at least one structural protein, at least one storage protein, at least one hormone protein, at least one receptor protein, at least one contractile protein, at least one antibody, at least one monoclonal antibody, or a combination thereof.

19. The contact lens of claim 1 , wherein said one or more drugs comprises an anti-inflammatory agent, an anti-allergy agent, an anti-infective agent, an antibiotic, an anti-parasitic agent, an anti-glaucoma agent, an anti-macular degeneration agent, an ophthalmic drug, a steroid, an anti-dry eye agent, a comfort agent, or a combination thereof.

20. The contact lens of claim 19 ,

wherein said comfort agent is hyaluronic acid (HA).

21. A contact lens; comprising:

a) a first surface and a second surface;

b) at least one Penetration Enhancer (PE); and

c) said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens;

1) said at least one coating comprising at least one three dimensional structure; and

2) said at least one three dimensional structure comprising:

a. one or more drug reservoir layers; wherein said one or more drug reservoir layers comprise one or more drugs; and

b. one or more barrier layers;

wherein said one or more barrier layers modulate the release of said one or more drugs from said drug delivery contact lens.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2023
From: DOSHI, PRAFUL
To: MEDIPRINT OPHTHALMICS INC.
Reel/Frame 062806/0864 →
Continuity (12)
Continuation 16826485 · Mar 23, 2020
Continuation 16524015 · Jul 27, 2019
Division 16188833 · Nov 13, 2018
Continuation In Part 16158587 · Oct 12, 2018
Continuation 16023156 · Jun 29, 2018
Division 15898329 · Feb 16, 2018
Division 15891456 · Feb 8, 2018
Division 13065904 · Apr 2, 2011
Provisional Application 61341824 · Apr 3, 2010
Provisional Application 62677021 · May 27, 2018
Provisional Application 62597272 · Dec 11, 2017
Related Publication 20210038509A1 · Feb 11, 2021